7.5 mg of prednisone/day (or equivalent) with evidence of decreased bone mineral density.Contraindicated in:
Use Cautiously in:
CV: atrial fibrillation.
Derm: erythema, photosensitivity, rash.
EENT: blurred vision, conjunctivitis, eye pain/inflammation.
GI: abdominal distention, abdominal pain, acid regurgitation, constipation, diarrhea, dyspepsia, dysphagia, esophageal cancer, esophageal ulcer, esophagitis, flatulence, gastritis, nausea, taste perversion, vomiting.
MS: musculoskeletal pain, femur fractures, osteonecrosis (primarily of jaw).
Neuro: headache.
Resp: asthma exacerbation.
Drug-Drug:
Drug-Food:
(Generic available)
Treatment of Osteoporosis
Prevention of Osteoporosis
Treatment of Corticosteroid-Induced Osteoporosis in Men and Women
Absorption: Poorly absorbed (0.6–0.8%) after oral administration.
Distribution: Transiently distributes to soft tissue, then distributes to bone.
Metabolism/Excretion: Excreted in urine.
Half-life: 10 yr (reflects release of drug from skeleton).
NDC Code*
